Latest Articles

  • Myasthenia gravis
    Mary Beth Keiter, MD
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 144-145; DOI: https://doi.org/10.3949/ccjm.81c.03003

    Readers comment on problems with the definition of myocardial infarction (December 2013) and on the diagnosis of myasthenia gravis (November 2013).

  • New hypertension guidelines: One size fits most?
    George Thomas, MD, MPH, Mehdi Shishehbor, DO, MPH, PhD, David Brill, DO and Joseph V. Nally, MD
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 178-188; DOI: https://doi.org/10.3949/ccjm.81a.14003

    The new report is more evidence-based and focused, outlining a strategy that is simpler and, in some instances, less aggressive.

  • Problems with myocardial infarction definitions
    Samer Antonios, MD
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 139; DOI: https://doi.org/10.3949/ccjm.81c.03001

    Readers comment on problems with the definition of myocardial infarction (December 2013) and on the diagnosis of myasthenia gravis (November 2013).

  • In reply: Myasthenia gravis
    Yuebing Li, MD, PhD, Yeeshu Arora, MD and Kerry Levin, MD
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 145; DOI: https://doi.org/10.3949/ccjm.81c.03004

    Readers comment on problems with the definition of myocardial infarction (December 2013) and on the diagnosis of myasthenia gravis (November 2013).

  • In reply: Problems with myocardial infarction definitions
    David M. Tehrani, MS and Arnold H. Seto, MD, MPA
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 139-144; DOI: https://doi.org/10.3949/ccjm.81c.03002

    Readers comment on problems with the definition of myocardial infarction (December 2013) and on the diagnosis of myasthenia gravis (November 2013).

  • When are effective medications just too expensive?
    Shivan J. Mehta, MD, MBA and David A. Asch, MD, MBA
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 173-175; DOI: https://doi.org/10.3949/ccjm.81a.14010

    Physicians may have been taught that it isn’t their job to think about costs—but they should.

  • Hepatitis C virus: Here comes all-oral treatment
    Hepatitis C virus: Here comes all-oral treatment
    Mohannad Dugum, MD and Robert O’shea, MD
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 159-172; DOI: https://doi.org/10.3949/ccjm.81a.13155

    Direct-acting antiviral drugs open the door for an all-oral regimen, potentially eliminating the need for interferon and thus avoiding its harsh side effects.

  • In Reply: Canagliflozin (November 2013)
    Mary Vouyiouklis, MD
    Cleveland Clinic Journal of Medicine February 2014, 81 (2) 90; DOI: https://doi.org/10.3949/ccjm.81c.02005
  • Reviewers 2013
    Cleveland Clinic Journal of Medicine February 2014, 81 (2) 102;
  • Managing risks of TNF inhibitors: An update for the internist
    Jennifer Hadam, MD, Elie Aoun, MD, MS, Kofi Clarke, MD and Mary Chester Wasko, MD, MSc
    Cleveland Clinic Journal of Medicine February 2014, 81 (2) 115-127; DOI: https://doi.org/10.3949/ccjm.81a.12121

    Tumor necrosis factor inhibitors pose infrequent but serious risks, including infection and malignancy.

Pages